# ITT Inc.: financial statements, quarterly ITT · NYSE · CIK 216228 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/itt.md) · [Financials](/companies/itt/financials.md) · [Filings](/companies/itt/filings.md) · [Insiders](/companies/itt/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/itt/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [822](/filings/0000216228-24-000081.md) | [829 d](/filings/0000216228-26-000012.md) | [911](/filings/0000216228-25-000031.md) | [906](/filings/0000216228-25-000052.md) | [885](/filings/0000216228-25-000061.md) | [929 d](/filings/0000216228-26-000012.md) | [913](/filings/0000216228-26-000036.md) | [972](/filings/0000216228-26-000065.md) | [999](/filings/0000216228-25-000061.md) | [1,054 d](/filings/0000216228-26-000012.md) | [1,212](/filings/0000216228-26-000036.md) | [1,473](/filings/0000216228-26-000065.md) | | Cost of revenue | $m | [543](/filings/0000216228-24-000081.md) | [541 d](/filings/0000216228-26-000012.md) | [609](/filings/0000216228-25-000031.md) | [589](/filings/0000216228-25-000052.md) | [571](/filings/0000216228-25-000061.md) | [613 d](/filings/0000216228-26-000012.md) | [590](/filings/0000216228-26-000036.md) | [622](/filings/0000216228-26-000065.md) | [644](/filings/0000216228-25-000061.md) | [680 d](/filings/0000216228-26-000012.md) | [783](/filings/0000216228-26-000036.md) | [963](/filings/0000216228-26-000065.md) | | Gross profit | $m | [279](/filings/0000216228-24-000081.md) | [288 d](/filings/0000216228-26-000012.md) | [302](/filings/0000216228-25-000031.md) | [317](/filings/0000216228-25-000052.md) | [315](/filings/0000216228-25-000061.md) | [316 d](/filings/0000216228-26-000012.md) | [323](/filings/0000216228-26-000036.md) | [351](/filings/0000216228-26-000065.md) | [355](/filings/0000216228-25-000061.md) | [374 d](/filings/0000216228-26-000012.md) | [429](/filings/0000216228-26-000036.md) | [510](/filings/0000216228-26-000065.md) | | Research and development | $m | [25.0](/filings/0000216228-24-000081.md) | [25.5 d](/filings/0000216228-26-000012.md) | [30.0](/filings/0000216228-25-000031.md) | [29.7](/filings/0000216228-25-000052.md) | [28.6](/filings/0000216228-25-000061.md) | [28.0 d](/filings/0000216228-26-000012.md) | [25.3](/filings/0000216228-26-000036.md) | [27.2](/filings/0000216228-26-000065.md) | [28.1](/filings/0000216228-25-000061.md) | [26.8 d](/filings/0000216228-26-000012.md) | [33.1](/filings/0000216228-26-000036.md) | [35.8](/filings/0000216228-26-000065.md) | | Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating income | $m | [143](/filings/0000216228-24-000081.md) | [121 d](/filings/0000216228-26-000012.md) | [150](/filings/0000216228-25-000031.md) | [160](/filings/0000216228-25-000052.md) | [209](/filings/0000216228-25-000061.md) | [160 d](/filings/0000216228-26-000012.md) | [151](/filings/0000216228-26-000036.md) | [175](/filings/0000216228-26-000065.md) | [180](/filings/0000216228-25-000061.md) | [179 d](/filings/0000216228-26-000012.md) | [141](/filings/0000216228-26-000036.md) | [180](/filings/0000216228-26-000065.md) | | Interest expense | $m | [4.2](/filings/0000216228-24-000081.md) | [3.8 d](/filings/0000216228-26-000012.md) | [7.7](/filings/0000216228-25-000031.md) | [7.4](/filings/0000216228-25-000052.md) | [10.0](/filings/0000216228-25-000061.md) | [11.5 d](/filings/0000216228-26-000012.md) | [9.3](/filings/0000216228-26-000036.md) | [12.6](/filings/0000216228-26-000065.md) | [11.7](/filings/0000216228-25-000061.md) | [14.5 d](/filings/0000216228-26-000012.md) | [24.7](/filings/0000216228-26-000036.md) | [49.7](/filings/0000216228-26-000065.md) | | Income tax | $m | [29.9](/filings/0000216228-24-000081.md) | [24.8 d](/filings/0000216228-26-000012.md) | [33.0](/filings/0000216228-25-000031.md) | [33.2](/filings/0000216228-25-000052.md) | [38.0](/filings/0000216228-25-000061.md) | [22.2 d](/filings/0000216228-26-000012.md) | [35.2](/filings/0000216228-26-000036.md) | [42.5](/filings/0000216228-26-000065.md) | [44.3](/filings/0000216228-25-000061.md) | [38.1 d](/filings/0000216228-26-000012.md) | [49.3](/filings/0000216228-26-000036.md) | [48.7](/filings/0000216228-26-000065.md) | | Net income | $m | [111](/filings/0000216228-24-000081.md) | [93.2 d](/filings/0000216228-26-000012.md) | [112](/filings/0000216228-25-000031.md) | [120](/filings/0000216228-25-000052.md) | [162](/filings/0000216228-25-000061.md) | [127 d](/filings/0000216228-26-000012.md) | [108](/filings/0000216228-26-000036.md) | [121](/filings/0000216228-26-000065.md) | [127](/filings/0000216228-25-000061.md) | [132 d](/filings/0000216228-26-000012.md) | [78.0](/filings/0000216228-26-000036.md) | [84.9](/filings/0000216228-26-000065.md) | | Diluted EPS | $ per share | [1.34](/filings/0000216228-24-000081.md) | not reported | [1.35](/filings/0000216228-25-000031.md) | [1.45](/filings/0000216228-25-000052.md) | [1.97](/filings/0000216228-25-000061.md) | not reported | [1.33](/filings/0000216228-26-000036.md) | [1.52](/filings/0000216228-26-000065.md) | [1.62](/filings/0000216228-25-000061.md) | not reported | [0.89](/filings/0000216228-26-000036.md) | [0.95](/filings/0000216228-26-000065.md) | | Basic EPS | $ per share | [1.35](/filings/0000216228-24-000081.md) | not reported | [1.36](/filings/0000216228-25-000031.md) | [1.46](/filings/0000216228-25-000052.md) | [1.98](/filings/0000216228-25-000061.md) | not reported | [1.33](/filings/0000216228-26-000036.md) | [1.53](/filings/0000216228-26-000065.md) | [1.63](/filings/0000216228-25-000061.md) | not reported | [0.89](/filings/0000216228-26-000036.md) | [0.95](/filings/0000216228-26-000065.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: not reported - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.4](/filings/0000216228-23-000039.md) | [0.5](/filings/0000216228-25-000014.md) | [0.4](/filings/0000216228-24-000033.md) | [0.4](/filings/0000216228-24-000055.md) | [0.5](/filings/0000216228-24-000081.md) | [0.4](/filings/0000216228-26-000012.md) | [0.4](/filings/0000216228-25-000031.md) | [0.5](/filings/0000216228-25-000052.md) | [0.5](/filings/0000216228-25-000061.md) | [1.7](/filings/0000216228-26-000065.md) | [0.6](/filings/0000216228-26-000036.md) | [0.6](/filings/0000216228-26-000065.md) | | Current assets | $bn | [1.8](/filings/0000216228-23-000039.md) | [1.9](/filings/0000216228-25-000014.md) | [1.9](/filings/0000216228-24-000033.md) | [1.9](/filings/0000216228-24-000055.md) | [2.0](/filings/0000216228-24-000081.md) | [1.9](/filings/0000216228-26-000012.md) | [2.0](/filings/0000216228-25-000031.md) | [2.1](/filings/0000216228-25-000052.md) | [2.1](/filings/0000216228-25-000061.md) | [3.4](/filings/0000216228-26-000065.md) | [2.9](/filings/0000216228-26-000036.md) | [2.8](/filings/0000216228-26-000065.md) | | Total assets | $bn | [3.8](/filings/0000216228-23-000039.md) | [3.9](/filings/0000216228-25-000014.md) | [4.4](/filings/0000216228-24-000033.md) | [4.4](/filings/0000216228-24-000055.md) | [4.9](/filings/0000216228-24-000081.md) | [4.7](/filings/0000216228-26-000012.md) | [4.8](/filings/0000216228-25-000031.md) | [5.0](/filings/0000216228-25-000052.md) | [5.1](/filings/0000216228-25-000061.md) | [6.3](/filings/0000216228-26-000065.md) | [11.1](/filings/0000216228-26-000036.md) | [11.0](/filings/0000216228-26-000065.md) | | Current liabilities | $bn | [1.0](/filings/0000216228-23-000039.md) | [1.0](/filings/0000216228-25-000014.md) | [1.2](/filings/0000216228-24-000033.md) | [1.2](/filings/0000216228-24-000055.md) | [1.3](/filings/0000216228-24-000081.md) | [1.3](/filings/0000216228-26-000012.md) | [1.7](/filings/0000216228-25-000031.md) | [1.4](/filings/0000216228-25-000052.md) | [1.4](/filings/0000216228-25-000061.md) | [1.3](/filings/0000216228-26-000065.md) | [1.9](/filings/0000216228-26-000036.md) | [2.3](/filings/0000216228-26-000065.md) | | Total liabilities | $bn | [1.4](/filings/0000216228-23-000039.md) | [1.4](/filings/0000216228-25-000014.md) | [1.8](/filings/0000216228-24-000033.md) | [1.8](/filings/0000216228-24-000055.md) | [2.2](/filings/0000216228-24-000081.md) | [1.9](/filings/0000216228-26-000012.md) | [2.0](/filings/0000216228-25-000031.md) | [2.5](/filings/0000216228-25-000052.md) | [2.4](/filings/0000216228-25-000061.md) | [2.2](/filings/0000216228-26-000065.md) | [6.4](/filings/0000216228-26-000036.md) | [6.2](/filings/0000216228-26-000065.md) | | Long-term debt | $bn | not reported | [0.0](/filings/0000216228-25-000014.md) | [0.2](/filings/0000216228-24-000033.md) | [0.2](/filings/0000216228-24-000055.md) | [0.5](/filings/0000216228-24-000081.md) | [0.2](/filings/0000216228-26-000012.md) | [0.0](/filings/0000216228-25-000031.md) | [0.6](/filings/0000216228-25-000052.md) | [0.6](/filings/0000216228-25-000061.md) | [0.5](/filings/0000216228-26-000012.md) | [3.4](/filings/0000216228-26-000036.md) | [2.9](/filings/0000216228-26-000065.md) | | Current portion of debt | $bn | [0.0](/filings/0000216228-23-000039.md) | [0.0](/filings/0000216228-25-000014.md) | [0.0](/filings/0000216228-24-000033.md) | [0.0](/filings/0000216228-24-000055.md) | [0.0](/filings/0000216228-24-000081.md) | [0.0](/filings/0000216228-26-000012.md) | [0.0](/filings/0000216228-25-000031.md) | [0.0](/filings/0000216228-25-000052.md) | [0.0](/filings/0000216228-25-000061.md) | [0.0](/filings/0000216228-26-000065.md) | [0.0](/filings/0000216228-26-000036.md) | [0.1](/filings/0000216228-26-000065.md) | | Short-term borrowings | $bn | [0.0](/filings/0000216228-23-000039.md) | [0.2](/filings/0000216228-25-000014.md) | [0.0](/filings/0000216228-24-000033.md) | [0.0](/filings/0000216228-24-000055.md) | [0.0](/filings/0000216228-24-000081.md) | [0.4](/filings/0000216228-26-000012.md) | [0.0](/filings/0000216228-25-000031.md) | [0.0](/filings/0000216228-25-000052.md) | [0.0](/filings/0000216228-25-000061.md) | [0.0](/filings/0000216228-26-000065.md) | [0.0](/filings/0000216228-26-000036.md) | [0.0](/filings/0000216228-26-000065.md) | | Shareholders' equity | $bn | [2.4](/filings/0000216228-23-000039.md) | [2.5](/filings/0000216228-25-000014.md) | [2.6](/filings/0000216228-24-000033.md) | [2.6](/filings/0000216228-24-000055.md) | [2.7](/filings/0000216228-24-000081.md) | [2.8](/filings/0000216228-26-000012.md) | [2.8](/filings/0000216228-25-000031.md) | [2.6](/filings/0000216228-25-000052.md) | [2.7](/filings/0000216228-25-000061.md) | [4.1](/filings/0000216228-26-000065.md) | [4.7](/filings/0000216228-26-000036.md) | [4.8](/filings/0000216228-26-000065.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [170 d](/filings/0000216228-24-000081.md) | [170 d](/filings/0000216228-26-000012.md) | [57.8](/filings/0000216228-25-000031.md) | [158 d](/filings/0000216228-25-000052.md) | [124 d](/filings/0000216228-25-000061.md) | [223 d](/filings/0000216228-26-000012.md) | [113](/filings/0000216228-26-000036.md) | [154 d](/filings/0000216228-26-000065.md) | [174 d](/filings/0000216228-25-000061.md) | [228 d](/filings/0000216228-26-000012.md) | [39.9](/filings/0000216228-26-000036.md) | [191 d](/filings/0000216228-26-000065.md) | | Capital expenditure | $m | [22.2 d](/filings/0000216228-24-000081.md) | [39.1 d](/filings/0000216228-26-000012.md) | [27.7](/filings/0000216228-25-000031.md) | [23.2 d](/filings/0000216228-25-000052.md) | [36.6 d](/filings/0000216228-25-000061.md) | [36.4 d](/filings/0000216228-26-000012.md) | [36.8](/filings/0000216228-26-000036.md) | [16.4 d](/filings/0000216228-26-000065.md) | [27.7 d](/filings/0000216228-25-000061.md) | [40.4 d](/filings/0000216228-26-000012.md) | [26.1](/filings/0000216228-26-000036.md) | [29.1 d](/filings/0000216228-26-000065.md) | | Dividends paid | $m | [23.8 d](/filings/0000216228-24-000081.md) | [23.9 d](/filings/0000216228-26-000012.md) | [26.5](/filings/0000216228-25-000031.md) | [26.1 d](/filings/0000216228-25-000052.md) | [26.1 d](/filings/0000216228-25-000061.md) | [26.0 d](/filings/0000216228-26-000012.md) | [28.7](/filings/0000216228-26-000036.md) | [27.5 d](/filings/0000216228-26-000065.md) | [27.3 d](/filings/0000216228-25-000061.md) | [27.5 d](/filings/0000216228-26-000012.md) | [35.0](/filings/0000216228-26-000036.md) | [34.5 d](/filings/0000216228-26-000065.md) | | Share repurchases | $m | [0.0 d](/filings/0000216228-24-000081.md) | [0.0 d](/filings/0000216228-26-000012.md) | [0.0](/filings/0000216228-25-000031.md) | [79.0 d](/filings/0000216228-25-000052.md) | [25.0 d](/filings/0000216228-25-000061.md) | [0.5 d](/filings/0000216228-26-000012.md) | [100](/filings/0000216228-26-000036.md) | [401 d](/filings/0000216228-26-000065.md) | [0.1 d](/filings/0000216228-25-000061.md) | [20.1 d](/filings/0000216228-26-000012.md) | [100](/filings/0000216228-26-000036.md) | [4.9 d](/filings/0000216228-26-000065.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations - Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [83.0](/filings/0000216228-23-000039.md) | [83.0](/filings/0000216228-24-000033.md) | [82.6](/filings/0000216228-24-000055.md) | [82.5](/filings/0000216228-24-000081.md) | [82.7](/filings/0000216228-25-000031.md) | [82.4](/filings/0000216228-25-000052.md) | [82.1](/filings/0000216228-25-000061.md) | [81.7](/filings/0000216228-26-000036.md) | [79.4](/filings/0000216228-26-000065.md) | [78.4](/filings/0000216228-25-000061.md) | [87.8](/filings/0000216228-26-000036.md) | [89.8](/filings/0000216228-26-000065.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 89,400,000 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0000216228-26-000065.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.